Chicago Partners Investment Group LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 11.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,518 shares of the company’s stock after acquiring an additional 265 shares during the period. Chicago Partners Investment Group LLC’s holdings in Zoetis were worth $476,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in ZTS. Whittier Trust Co. boosted its position in shares of Zoetis by 3.2% during the 1st quarter. Whittier Trust Co. now owns 10,810 shares of the company’s stock worth $1,829,000 after acquiring an additional 332 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in shares of Zoetis by 8.0% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 2,792 shares of the company’s stock worth $472,000 after acquiring an additional 208 shares in the last quarter. Central Pacific Bank Trust Division acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $509,000. Proficio Capital Partners LLC boosted its position in shares of Zoetis by 6.5% during the 1st quarter. Proficio Capital Partners LLC now owns 2,761 shares of the company’s stock worth $467,000 after acquiring an additional 169 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Zoetis by 58.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock worth $7,095,000 after acquiring an additional 15,491 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on ZTS. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $221.44.
Zoetis Price Performance
Shares of NYSE:ZTS opened at $175.18 on Tuesday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm’s fifty day moving average is $188.84 and its 200-day moving average is $179.03. The firm has a market cap of $79.37 billion, a PE ratio of 34.28, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the firm earned $1.41 earnings per share. Zoetis’s quarterly revenue was up 8.3% on a year-over-year basis. Sell-side analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.
Zoetis Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is presently 33.66%.
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- How to invest in marijuana stocks in 7 steps
- Intel: Is Now the Time to Be Brave?
- Comparing and Trading High PE Ratio Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- The Significance of Brokerage Rankings in Stock Selection
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.